CTIS2022-502814-99-00进行中（未招募）1 期
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Food effect and pharmacokinetics study in healthy, male volunteers with P2202CTRI/2010/091/002992Piramal Enterprises Limited32
进行中（未招募）
1 期
A study in healthy volunteers to look at how the test medicine, COMP360, is taken up by the body when given as two different strength capsulesTreatment-resistant depressionISRCTN16636661COMPASS Pathfinder Limited14
已完成
不适用
A phase 1, open-label, randomized, 2-period, 2-sequence, crossover study to evaluate the bioequivalence of Bosutinib pediatric capsule and the commercial tablet formulations in healthy participants under fed conditiochronic myeloid leukemia10024324NL-OMON49458Pfizer, Inc.66
进行中（未招募）
1 期
A two part Open-Label, Randomized, Phase II/III clinical study to examine how safe and how well Dinutuximab works on it’s own or in combination with Irinotecan when treating patients with small cell lung cancer that is unresponsive or no longer responding to previous treatmentrelapsed or refractory small cell lung cancer (SCLC)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000758-20-SKnited Therapeutics Corporation485
进行中（未招募）
1 期
A two part Open-Label, Randomized, Phase II/III clinical study to examine how safe and how well Dinutuximab works on it’s own or in combination with Irinotecan when treating patients with small cell lung cancer that is unresponsive or no longer responding to previous treatmentrelapsed or refractory small cell lung cancer (SCLC)MedDRA version: 20.0Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000758-20-PLnited Therapeutics Corporation470